RankingsPricing
  1. US-listed companies
  2. CRISPR Therapeutics AG
  3. Financials
  4. Total non-current liabilities

CRISPR Therapeutics AGCRSP

Market cap
$4.7B
P/E ratio
SummaryFinancials
Period EndTotal non-current liabilities (Million USD)YoY (%)
Dec 31, 2024222-6.64%
Dec 31, 2023238-3.45%
Dec 31, 2022246+5.99%
Dec 31, 2021233+234.71%
Dec 31, 202069-1.07%
Dec 31, 201970+1.66%
Dec 31, 201869+0.10%
Dec 31, 201769-23.43%
Dec 31, 201690

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)